At the ESMO Congress 2023, our mission with the newspaper articles and expert opinions is to disseminate clear information from the studies presented and help understand their potential impact on cancer care
The work done this year to cover and select all novelties coming to the ESMO Congress 2023 has been challenging due to the many important studies which will be presented.
The behind-the-scenes work of the ESMO Daily Reporter Editorial team has been impressive: 2,546 abstracts have been accepted for presentation, including 108 late-breaking abstracts, many of which will be discussed at Presidential sessions. We have selected those which are crucial to our daily work and may play a key role for the oncology community. Key opinion leaders in the field have been identified to put new data into context and give their own perspectives to practicing oncologists and researchers on how these novelties will impact on cancer care.
While we will hear the voice of patient advocates about their feelings toward the use of digital tools, we will take a closer look at how digitalization is helping clinicians to involve patients into patient-oriented programmes and coach them to oral treatments.
An in-depth article on the latest applications of artificial intelligence (AI) will show how they can be useful in clinical settings, from single cell analysis to radiological imaging, based on some new promising data presented at the Congress and a glimpse to the future.
For patients with non-small cell lung cancer many trials will be presented as late-breaking and for patients with EGFR mutations treatment in first and further lines might change upon the data presented in Madrid this year.
With the commentaries of renowned experts, some newspaper articles will address complex questions such as how to treat patients upon resistance to immunotherapy and how new combinations improve the outcome in case of targetable alterations.
By reading our news, you will learn more on innovation through immunotherapy approaches, which are bringing important results for patients with solid tumours, with the use of different T- cell products, and the role of immune checkpoint inhibitors in early breast cancer and gynecological cancers. In addition, the implementation of liquid biopsy into the management of patients with cancer will be discussed for different tumour types: we will dedicate an article to explain the different approaches and the useful information derived from these studies.
Without any doubt, the data presented at this year’s ESMO Congress will be inspiring for all those with an interest in oncology and we hope to guide you through groundbreaking research with expert opinions, critical perspectives and take-home messages.
From the ESMO Daily Reporter Editorial Team, we wish you a wonderful ESMO 2023!
ESMO Congress 2023
Check the online programme and find out the abstracts that will be presented in Madrid, Spain.
